| pubmed-article:8271861 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8271861 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8271861 | lifeskim:mentions | umls-concept:C0836924 | lld:lifeskim |
| pubmed-article:8271861 | lifeskim:mentions | umls-concept:C0021747 | lld:lifeskim |
| pubmed-article:8271861 | lifeskim:mentions | umls-concept:C0039082 | lld:lifeskim |
| pubmed-article:8271861 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:8271861 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:8271861 | lifeskim:mentions | umls-concept:C1518422 | lld:lifeskim |
| pubmed-article:8271861 | pubmed:issue | 16 | lld:pubmed |
| pubmed-article:8271861 | pubmed:dateCreated | 1994-2-2 | lld:pubmed |
| pubmed-article:8271861 | pubmed:abstractText | The effect of interferons in the correction of thrombocytosis in chronic myeloproliferative syndromes is well known. In this study the efficacy of alpha-2b interferon in a regimen of induction followed by a phase of sequential maintenance to progressively decreasing doses was evaluated with the aim of knowing the minimum doses necessary to maintain response. | lld:pubmed |
| pubmed-article:8271861 | pubmed:language | spa | lld:pubmed |
| pubmed-article:8271861 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8271861 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8271861 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8271861 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8271861 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8271861 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8271861 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:8271861 | pubmed:issn | 0025-7753 | lld:pubmed |
| pubmed-article:8271861 | pubmed:author | pubmed-author:PetitJJ | lld:pubmed |
| pubmed-article:8271861 | pubmed:author | pubmed-author:BesserBB | lld:pubmed |
| pubmed-article:8271861 | pubmed:author | pubmed-author:MazzaC JCJ | lld:pubmed |
| pubmed-article:8271861 | pubmed:author | pubmed-author:Domingo... | lld:pubmed |
| pubmed-article:8271861 | pubmed:author | pubmed-author:CallísMM | lld:pubmed |
| pubmed-article:8271861 | pubmed:author | pubmed-author:Fernández... | lld:pubmed |
| pubmed-article:8271861 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8271861 | pubmed:day | 13 | lld:pubmed |
| pubmed-article:8271861 | pubmed:volume | 101 | lld:pubmed |
| pubmed-article:8271861 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8271861 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8271861 | pubmed:pagination | 601-3 | lld:pubmed |
| pubmed-article:8271861 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:meshHeading | pubmed-meshheading:8271861-... | lld:pubmed |
| pubmed-article:8271861 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8271861 | pubmed:articleTitle | [Alfa-2b interferon in the treatment of thrombocytosis associated to chronic non leukemic myeloproliferative syndromes]. | lld:pubmed |
| pubmed-article:8271861 | pubmed:affiliation | Servicio de Hematología Clínica, Ciutat Sanitària, Universitària de Bellvitge-Hospital Duran i Reynals L'Hospitalet de Llobregat, Barcelona. | lld:pubmed |
| pubmed-article:8271861 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8271861 | pubmed:publicationType | English Abstract | lld:pubmed |
